Overview EVA: Evista Alendronate Comparison Status: Completed Trial end date: 1969-12-31 Target enrollment: Participant gender: Summary The purpose of this study is to determine how treatment with raloxifene compares to treatment with alendronate in postmenopausal women with osteoporosis on the chance of experiencing fractures Phase: Phase 4 Details Lead Sponsor: Eli Lilly and CompanyTreatments: AlendronateRaloxifene Hydrochloride